Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study

Authors:

Abstract
No abstract available

This publication has 28 references indexed in Scilit: